Test ID: PTNT
Prothrombin G20210A Mutation, Blood
NY State Approved 
Indicates the status of NY State approval and if the test is orderable for NY State clients.
Yes
Useful For Suggests clinical disorders or settings where the test may be helpful
Direct mutation analysis for the prothrombin (PT) G20210A allele should be reserved for patients with clinically suspected thrombophilia. There may be additional indications for direct PT G20210A mutation testing, such as in determining the duration of anticoagulation therapy of venous thromboembolism patients and screening for women contemplating hormone therapy.
Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test
Method Name A short description of the method used to perform the test
Direct Mutation Analysis
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
Prothrombin G20210A Mutation, B
Aliases Lists additional common names for a test, as an aid in searching
Factor II 20210 mutation
Prothrombin 20210 mutation
Prothrombin Nucleotide
PTNT
Prothrombin 20210 mutation
Prothrombin Nucleotide
PTNT
External
link
PDF
document
Excel
document
Word
document